Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

74 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Chronic Thromboembolic Pulmonary Hypertension (CTEPH) NCT02429284

- 01/03/19 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
U.S. CTEPH Registry; ODM derived from: https://clinicaltrials.gov/show/NCT02429284

Eligibility Pulmonary Hypertension NCT00373360

- 20/09/21 - 1 modulo, 2 itemgroups, 18 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin; ODM derived from: https://clinicaltrials.gov/show/NCT00373360

Eligibility Hypertension, Pulmonary NCT01342952

- 26/05/20 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529; ODM derived from: https://clinicaltrials.gov/show/NCT01342952

Eligibility Hypertension, Pulmonary NCT01332331

- 25/05/20 - 1 modulo, 2 itemgroups, 19 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Ambrisentan in Children 8-18yrs; ODM derived from: https://clinicaltrials.gov/show/NCT01332331

Eligibility Hypertension, Pulmonary NCT01305252

- 25/05/20 - 1 modulo, 3 itemgroups, 29 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria, Exclusion Criteria
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil), 2 FDA Approved Pulmonary Hypertension Medications; ODM derived from: https://clinicaltrials.gov/show/NCT01305252

Eligibility Hypertension, Pulmonary NCT01247116

- 24/05/20 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT01247116

Eligibility Hypertension, Pulmonary NCT01178073

- 24/05/20 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH); ODM derived from: https://clinicaltrials.gov/show/NCT01178073

Eligibility Pulmonary Hypertension NCT02053246

- 26/06/19 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT02053246

Eligibility Hypertension, Pulmonary NCT02007629

- 18/04/19 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor; ODM derived from: https://clinicaltrials.gov/show/NCT02007629

Eligibility Pulmonary Hypertension NCT02345616

- 17/01/19 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility; ODM derived from: https://clinicaltrials.gov/show/NCT02345616

Eligibility Pulmonary Hypertension NCT01126411

- 24/09/18 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Immunoadsorption in Patients With Pulmonary Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT01126411

Eligibility Pulmonary Hypertension NCT01100008

- 24/09/18 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion; ODM derived from: https://clinicaltrials.gov/show/NCT01100008

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial